You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

Leading medical-scientific event on Hemophilia held in Trieste, Italy

Kedrion-organized congress put replacement therapy, personalization and access to care in the spotlight

read more 

EVENTS

Kedrion scientific symposium at the 2019 PNS Conference in Genoa, Italy

A chance for world Key Opinion Leaders to debate possible new therapies for the treatment of CIPN

read more 

PLASMA & BIOTHERAPIES

First patient enrolled and treated in Kedrion’s CARES10 clinical study

Phase 3 study to assess efficacy, safety and pharmacokinetics of a 10% IVIg in the treatment of adult PID patients

read more 
  1. Kedrion - Feature thumbnail

    CORPORATE - 28-12-2016

    Kedrion Biopharma strengthens its presence in Russia

    Memorandum of Understanding with Russian pharmaceutical companies for a joint plasma products manufacturing program

    read more 

  2. PLASMA & BIOTHERAPIES - 08-11-2016

    FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin

    Announcement by Kedrion Biopharma and Kamada. Regulatory decision expected in August 2017

    read more 

  3. FEATURED STORIES - 24-10-2016

    Hemophilia seen through children's eyes: Kedrion teams up with LA Kelley

    Three books of the series My First Factor Creation are now available for free download

    read more 

  4. EVENTS - 17-10-2016

    Kedrion took part in the 17th ESID Meeting with 44 international guests

    The conference focused on new insights into PIDs’ diagnosis and therapies

    read more 

Pages

For more information please contact: pressoffice@kedrion.com